CASP9 and adrenal cortex carcinoma: The results indicated that ACC patients with high expression of CASP3 (Figure 4A, p = 0.016), CASP9 (Figure 4B, p = 0.001), NLRC4 (Figure 4C, p = 0.018), GSDMB (Figure 4D, p = 0.034), GSDMD (Figure 4E, p = 0.013), PRKACA (Figure 4F, p = 0.007), and SCAF11 (Figure 4G, p = 0.018) have a poor survival rate.